Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment.
Autoimmunity results from a failure in central and/or peripheral tolerance; however, the events that initiate and maintain this dysfunction remain unclear. To better understand the mediators involved in autoimmunity, we investigated the cellular mechanisms maintaining disease in the (SWR x NZB)F(1) (SNF(1)) mouse model of systemic lupus erythematosus. Previously, we have shown that autoimmunity in this model is dependent on CD40-CD154 interactions. Herein, our studies reveal that the severity of disease in SNF(1) mice correlates with a marked increase in the frequency of apoptotic splenocytes, including a higher proportion of apoptotic dendritic cells (DC) in vivo. In addition, we demonstrate a significant disease-related increase in the absolute number of splenic CD11c(high) DC. The increased DC number appears to be attributable to DC proliferation and enhanced migration to the spleen, most likely induced by elevated splenic expression of secondary lymphoid chemokine. Importantly, these imbalances in apoptosis, secondary lymphoid chemokine expression, and DC homeostasis were reduced or normalized by anti-CD154 treatment. Thus, our data demonstrate CD154-dependent regulation of apoptosis and DC homeostasis in mice with lupus-like autoimmune disease. We suggest that these mechanisms comprise an autostimulatory loop, maintaining the cascade of autoimmunity by DC presentation of self-Ags derived from apoptotic cells and CD154-mediated costimulation.
Kalled
S L
SL
Department of Immunology and Inflammation, Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA. susan_kalled@biogen.com
Cutler
A H
AH
Burkly
L C
LC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017209:Apoptosis / Q000235:genetics / Q000276:immunology*; D023201:CD40 Ligand / Q000276:immunology*; D002452:Cell Count; D002455:Cell Division / Q000235:genetics / Q000276:immunology; D002465:Cell Movement / Q000235:genetics / Q000276:immunology; D054421:Chemokine CCL21; D019742:Chemokines, CC / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D003433:Crosses, Genetic; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology*; D015536:Down-Regulation / Q000276:immunology; D005260:Female; D006706:Homeostasis / Q000235:genetics / Q000276:immunology*; D016130:Immunophenotyping; D008181:Lupus Nephritis / Q000235:genetics / Q000276:immunology* / Q000473:pathology* / Q000517:prevention & control; D008213:Lymphocyte Activation / Q000235:genetics; D051379:Mice; D008814:Mice, Inbred NZB; D012720:Severity of Illness Index; D013154:Spleen / Q000276:immunology / Q000378:metabolism / Q000473:pathology
D000911:Antibodies, Monoclonal; C515479:Ccl21c protein, mouse; D054421:Chemokine CCL21; D019742:Chemokines, CC; D023201:CD40 Ligand